About Delta CTSC
Vision and Strategic Goals
The The Delta Clinical and Translational Science Consortium DCTSC was initiated to facilitate and grow Clinical and Translational Research CTR in a three state region (Tennessee, Mississippi, Louisiana) of the South with a focus on rural health and health disparities across the life span. Through this research we believe a reduction can be achieved in morbidity and mortality risk from chronic diseases among our residents, many of whom have limited access to health care. Combined with the profound impact of poverty in the region, residents in the Delta Region experience persistent and significant, health disparities.
By 2023, the Delta Clinical and Translational Science Consortium will create an interdisciplinary model environment that spans three states and facilitates research from investigation through discovery to translation into real-life practice, thereby accelerating the translation of basic research to practical improvement in human health.
The Delta Clinical and Translational Science Consortium develops, demonstrates, and shares methods and approaches to advance translational research, by providing education and training, fostering interdisciplinary teams, improving quality and efficiency, and engaging community stakeholders and partners in meaningful collaboration. The Consortium is committed to rigorous and continuous evaluation to guide decision-making and promote innovation in clinical and translational research.
To reduce and/or lessen the morbidity and mortality risk from chronic disease and other disease burdens in entire populations, especially in rural, low-income, and racial/ethnic minority populations in Louisiana, Mississippi, and Tennessee who are negatively affected by factors such as socioeconomic status, geographical challenges and health disparities.
Translating biomedical discoveries into clinical applications that improve human health is complex and often difficult, resulting in substantial delays of health benefits for patients and communities. Recognizing the need to improve translation, the National Institutes of Health (NIH) established the Clinical and Translational Science Awards (CTSA) program. In 2011, the CTSA program became part of the National Center for Advancing Translational Sciences (NCATS), whose mission is the acceleration of the process of transforming discovery to application while increasing the rate of adoption in clinical practice and by the community to improve human health. NCATS’ CTSA program supports a national network of institutions that collaborate to improve how clinical and translational science is conducted.
Our DCTSC proposal, submitted in Fall 2018, is responding to the published funding opportunity, Clinical and Translational Science Award (U54) PAR- 18-464. Our application also directly responds to the congressional priorities for the CTSA program stated in FY 2019 House Labor–HHS-Education Funding Bill “The (House Appropriations) Committee continues and encourages NCATS, through its CTSA program, to enhance its commitment to the value of translational science and funding for universities to continue to innovate by leveraging statewide resources and capabilities to improve rural health outcomes and eliminate health disparities.